tumor-infiltrating

(Z)-Leukadherin-1 (ADH-503 free base) 是 CD11b 的变构激动剂。

ADH-503 (GB1275) 是一种可口服的变构CD11b的小分子激动剂，可以导致肿瘤相关巨噬细胞的复极化、肿瘤浸润免疫抑制性髓系细胞数量的减少以及增强树突状细胞反应。

AZ10397767 is a potent CXCR2 antagonist (IC50 = 1 nM). AZ10397767 significantly reduced the numbers of infiltrating neutrophils into both in vitro and in vivo tumor models.

CB-1158-analog, also known as Numidargistat-analog and INCB01158-analog, is a potent and orally active arginase inhibitor with IC50=89 nM) . CB-1158 blocked myeloid cell-mediated suppression of T cell proliferation in vitro and reduced tumor growth in multiple mouse models of cancer, as a single agent and in combination with checkpoint blockade, adoptive T cell therapy, adoptive NK cell therapy, and the chemotherapy agent gemcitabine. CB-1158 increased tumor-infiltrating CD8+ T cells and NK cells, inflammatory cytokines, and expression of interferon-inducible genes. CB-1158 may be potentially useful in renal cell cancer, breast cancer, non-small cell lung cancer, acute myeloid leukemia, and other tumor types where arginase-secreting MDSCs are known to play an immunosuppressive role. (see ADDITIONAL INFORMATION in this web page for CB-1158 structure confusion).

Tyrosinase(206-214), human (AFLPWHRLF)，一种由9个氨基酸组成的肽，为酪氨酸酶的表位。可被HLA-A24限制性肿瘤浸润淋巴细胞(TIL)识别的Tyrosinase(206-214), human，具有重要生物医学意义。

PD-L1-IN-2是一种具有潜力的肿瘤免疫治疗剂，具有抑制PD-L1的活性。该化合物为Naamidine J的衍生物，可通过降低体内PD-L1的表达并增强肿瘤浸润性T细胞的免疫反应来发挥抗肿瘤效果。PD-L1-IN-2主要应用于结直肠癌的研究领域。

SWS1为d-(+)-生物素缀合的PD-L1抑制剂(IC50: 1.8 nM)，显示出抗癌潜力。该化合物能提高肿瘤浸润淋巴细胞数量，并在B16-F10小鼠模型中展现抗肿瘤效果(TGI=66.1%)。